Cytogenetics News and Research RSS Feed - Cytogenetics News and Research

Persistent leukemia-associated genetic mutations linked to increased risk of relapse, reduced overall survival

Persistent leukemia-associated genetic mutations linked to increased risk of relapse, reduced overall survival

In preliminary research, the detection of persistent leukemia-associated genetic mutations in at least 5 percent of bone marrow cells in day 30 remission samples among adult patients with acute myeloid leukemia was associated with an increased risk of relapse and reduced overall survival, according to a study in the August 25 issue of JAMA. [More]
FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy. [More]
New ACMG Scope of Practice of the Specialty of Medical Genetics document released

New ACMG Scope of Practice of the Specialty of Medical Genetics document released

The field of medical genetics is swiftly evolving. It's a period of rapid scientific discovery, new technologies and subsequent translation into medical practice, public policy and public health. But what role should the Medical Genetics specialist have since genetics impacts all patients and specialties in some way? In an effort to clearly define the changing role of the specialty of Medical Genetics and the distinction between Medical Geneticists and other genetics healthcare professionals, the American College of Medical Genetics and Genomics has has just released a new "Scope of Practice of the Specialty of Medical Genetics" document, revising its earlier 2008 Policy Statement. [More]
Rare BCR-ABL fusions highlighted in CML

Rare BCR-ABL fusions highlighted in CML

Chronic myeloid leukaemia patients with rare BCR-ABL fusions may be missed by quantitative polymerase chain reaction, research suggests. [More]
NeoGenomics' revenue increases 18% to $24.3 million in second quarter 2015

NeoGenomics' revenue increases 18% to $24.3 million in second quarter 2015

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, today reported its results for the second quarter of 2015. [More]
NeoGenomics announces launch of new germline cancer predisposition testing services

NeoGenomics announces launch of new germline cancer predisposition testing services

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of a new line of germline cancer predisposition testing services. The new tests include comprehensive testing for BRCA1 and BRCA2 encompassing an analysis of all exons and adjacent intronic regions. [More]
Chromosomal abnormalities in embryos created for IVF can be predicted at earliest stage of human development

Chromosomal abnormalities in embryos created for IVF can be predicted at earliest stage of human development

Scientists at Oregon Health & Science University, Stanford University, University of Valencia and IGENOMIX have discovered that chromosomal abnormalities in human embryos created for in vitro fertilization, or IVF, can be predicted within the first 30 hours of development at the cell-1 stage which results from the union of a female egg and male sperm. [More]
Investments in cloud-based laboratory information management systems are part of Europe’s eHealth strategy

Investments in cloud-based laboratory information management systems are part of Europe’s eHealth strategy

Investments in cloud-based laboratory information management systems are part of Europe’s eHealth strategy. [More]
NeoGenomics announces launch of new NeoLAB assays to diagnose hematologic diseases

NeoGenomics announces launch of new NeoLAB assays to diagnose hematologic diseases

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of its first twelve tests in a new line of "liquid biopsy" or NeoLAB assays using next generation sequencing and other advanced molecular technologies. [More]
Non-invasive prenatal testing can detect maternal cancer at early stage

Non-invasive prenatal testing can detect maternal cancer at early stage

Non-invasive prenatal testing (NIPT) for chromosomal foetal disorders is used increasingly to test for conditions such as Down's syndrome. NIPT examines DNA from the foetus in the mother's blood, and therefore does not carry the risk of miscarriage involved in invasive testing methods. [More]
Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers. [More]
NeoGenomics' revenue increases 27% to $23.0 million in first quarter 2015

NeoGenomics' revenue increases 27% to $23.0 million in first quarter 2015

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the first quarter of 2015. [More]
NeoGenomics' revenue increases 36% to $25.0 million in fourth quarter 2014

NeoGenomics' revenue increases 36% to $25.0 million in fourth quarter 2014

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the fourth quarter and full year of 2014. [More]
OGT study explores successful adoption of CytoSure ISCA array at Sheffield Children's NHS Foundation Trust

OGT study explores successful adoption of CytoSure ISCA array at Sheffield Children's NHS Foundation Trust

Oxford Gene Technology, The Molecular Genetics Company, explores how Sheffield Children's NHS Foundation Trust has seamlessly transferred to its CytoSure ISCA 8x60k platform, in a new case study entitled Evaluating and switching to CytoSure microarrays. As the result of a highly stringent National Health Service tender for the supply of oligo-based cytogenetics research arrays, CytoSure was selected based on the quality of data and analysis software. [More]
Leica Biosystems, Mayo Clinic partner to develop next generation of cytogenetics imaging software

Leica Biosystems, Mayo Clinic partner to develop next generation of cytogenetics imaging software

Leica Biosystems and Mayo Clinic's Department of Laboratory Medicine and Pathology announced today a collaboration to develop the next generation of cytogenetics imaging software. The new tool will optimize software workflow and improve the overall user experience for cytogenetics imaging technicians. [More]
Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow blasts in older patients with newly diagnosed Acute Myeloid Leukemia (AML). [More]
Scientists identify new biomarker for diagnosing cause of thyroid cancer

Scientists identify new biomarker for diagnosing cause of thyroid cancer

The expression of the protein CLIP2 provides information on whether a papillary thyroid carcinoma was induced by radiation or had a sporadic origin. With this discovery, scientists from the Helmholtz Zentrum München have identified a new biomarker for the diagnosis of the cancer cause. [More]
Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis. [More]
OGT to highlight NGS and FISH methods for tumour screening at BSGM 2014

OGT to highlight NGS and FISH methods for tumour screening at BSGM 2014

Oxford Gene Technology, The Molecular Genetics Company, is inviting attendees of the British Society for Genetic Medicine annual conference to its seminar entitled ‘Approaches to tumour screening and therapy stratification: case studies in Non-Small Cell Lung Cancer’ on Monday 22nd September, 13.10-13.50, room 2N. [More]
CAP awards accreditation to The Children's Hospital of Philadelphia Pathology & Laboratory Medicine

CAP awards accreditation to The Children's Hospital of Philadelphia Pathology & Laboratory Medicine

The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to The Children's Hospital of Philadelphia Pathology & Laboratory Medicine, Philadelphia, Pennsylvania based on results of a recent on-site inspection as part of the CAP's Accreditation Programs. [More]
Advertisement
Advertisement